Microvolt T-wave alternans testing provides a reliable means of guiding anti-arrhythmic therapy
Name
20120407-Letter to American Heart Journal.pdf
Size
15.56 KB
Format
Adobe PDF
Checksum (MD5)
cdea15d8980e588106ea634808f93fdb
Author(s)
Hohnloser, Stefan H.
Cohen, Richard J.
Date Issued
October 2012
Journal
American Heart Journal
Publisher
Elsevier B.V.
Citation
Hohnloser, Stefan H., and Richard J. Cohen. Microvolt T-wave Alternans Testing Provides a Reliable Means of Guiding Anti-arrhythmic Therapy. American Heart Journal 164, no. 4 (October 2012): e7.
Version
Author's final manuscript
Abstract
Gupta et al1 present a meta-analysis and conclude that microvolt T-wave alternans testing (MTWA) does not modify risk of sudden cardiac death (SCD) sufficiently for clinical use. Their analysis involves a number of methodological limitations. The authors included in their primary analysis numerous surrogates for sudden cardiac death (SCD) such as ICD therapy, cardiac mortality and total mortality.
MIT Department
Whitaker College of Health Sciences and Technology
Harvard University--MIT Division of Health Sciences and Technology
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike 3.0
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/j.ahj.2012.07.014
